Management of refractory cases of catastrophic antiphospholipid syndrome

Autoimmunity Reviews

Volumn 10, Issue 11, 2011, Pages 664-668

  Espinosa, Gerard ^a   Berman, Horacio ^a   Cervera, Ricard ^a  

^a HOSPITAL CLÍNIC   (Spain)

Author keywords

Anticardiolipin antobodies; Catastrophic antiphospholipid syndrome; Defibrotide; Eculizumab; Lupus anticoagulant; Refractory; Rituximab

Indexed keywords

ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; BENDAMUSTINE; BOSENTAN; CYCLOPHOSPHAMIDE; DEFIBROTIDE; DIPYRIDAMOLE; ECULIZUMAB; FIBRINOLYTIC AGENT; GLUCOCORTICOID; HEPARIN; ILOPROST; IMMUNOGLOBULIN; PROSTACYCLIN; RITUXIMAB; VON WILLEBRAND FACTOR CLEAVING PROTEINASE; WARFARIN;

ANTICOAGULANT THERAPY; ANTIPHOSPHOLIPID SYNDROME; B CELL LYMPHOMA; CHRONIC VEIN INSUFFICIENCY; CLINICAL FEATURE; CONTINUOUS INFUSION; CORTICOSTEROID THERAPY; DEEP VEIN THROMBOSIS; DRUG DOSE ESCALATION; DRUG MEGADOSE; EMBOLECTOMY; ENZYME ACTIVITY; FOLLICULAR LYMPHOMA; HUMAN; IMMUNOTHERAPY; INTERMITTENT CLAUDICATION; LABORATORY TEST; LIVER VENOOCCLUSIVE DISEASE; LOW DRUG DOSE; LUPUS ERYTHEMATOSUS NEPHRITIS; MORTALITY; PAROXYSMAL NOCTURNAL HEMOGLOBINURIA; PLASMAPHERESIS; RECURRENT DISEASE; RELAPSE; REVIEW; RHEUMATOID ARTHRITIS; SYSTEMIC LUPUS ERYTHEMATOSUS; THROMBOPHLEBITIS; THROMBOSIS; THROMBOTIC THROMBOCYTOPENIC PURPURA; TREATMENT RESPONSE;

ANTIBODIES, MONOCLONAL, HUMANIZED; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; ANTICOAGULANTS; ANTIPHOSPHOLIPID SYNDROME; CATASTROPHIC ILLNESS; GLUCOCORTICOIDS; HUMANS; IMMUNOGLOBULINS, INTRAVENOUS; IMMUNOTHERAPY; MULTIPLE ORGAN FAILURE; PLASMA EXCHANGE; POLYDEOXYRIBONUCLEOTIDES; RECURRENCE; THROMBOSIS; TREATMENT OUTCOME;

EID: 80052263703     PISSN: 15689972     EISSN: 18730183     Source Type: Journal    
DOI: 10.1016/j.autrev.2011.04.031     Document Type: Review

References (28)

1. Cervera R., Bucciarelli S., Espinosa G., et al. Catastrophic antiphospholipid syndrome: lessons from the "CAPS Registry" - a tribute to the late Josep Font. Ann NY Acad Sci 2007, 1108:448-456.
2. Bucciarelli S., Cervera R., Espinosa G., Gómez-Puerta J.A., Ramos-Casals M., Font J. Mortality in the catastrophic antiphospholipid syndrome: causes of death and prognostic factors. Autoimmun Rev 2006, 6:72-75.
3. Espinosa G., Cervera R., Asherson R.A. Catastrophic antiphospholipid syndrome and sepsis: a common link?. J Rheumatol 2007, 34:923-926.
4. Espinosa G., Bucciarelli S., Asherson R.A., Cervera R. Morbidity and mortality in the catastrophic antiphospholipid syndrome: pathophysiology, causes of death, and prognostic factors. Semin Thromb Haemost 2008, 34:288-292.
5. Bucciarelli S., Espinosa G., Cervera R., et al. Mortality in the catastrophic antiphospholipid syndrome: causes of death and prognostic factors in a series of 250 patients. Arthritis Rheum 2006, 54:2568-2576.
6. Asherson R.A., Espinosa G., Menahem S., et al. Relapsing catastrophic antiphospholipid syndrome: report of three cases. Semin Arthritis Rheum 2008, 37:366-372.
7. Bucciarelli S., Espinosa G., Bove A., Cervera R., Asherson R.A., for the CAPS Registry Project Group (European Forum on Antiphospholipid Antibodies) Relapsing Catastrophic Antiphospholipid Syndrome: Potential Role of Microangiopathic Hemolytic Anemia in Disease Relapses. American College of Rheumatology National Meeting 2007, Abstract 1397.
8. Cervera R., Bucciarelli S., Plasín M.A., et al. Catastrophic antiphospholipid syndrome (CAPS): descriptive analysis of a series of 280 patients from the "CAPS Registry". J Autoimmun 2009, 32:240-245.
9. Espinosa G., Bucciarelli S., Cervera R., et al. Thrombotic microangiopathic haemolytic anaemia and antiphospholipid antibodies. Ann Rheum Dis 2004, 63:730-736.
10. Lämmle B., Kremer Hovinga J.A., Alberio L. Thrombotic thrombocytopenic purpura. J Thromb Haemost 2005, 3:1663-1675.
11. Austin S.K., Starke R.D., Lawrie A.S., Cohen H., Machin S.J., Mackie I.J. The VWF/ADAMTS13 axis in the antiphospholipid syndrome: ADAMTS13 antibodies and ADAMTS13 dysfunction. Br J Haematol 2008, 141:536-544.
12. Ramos-Casals M., Soto M.J., Cuadrado M.J., Khamashta M.A. Rituximab in systemic lupus erythematosus. A systematic review of off-label use in 188 cases. Lupus 2009, 18:767-776.
13. Erre G.L., Pardini S., Faedda R., Passiu G. Effect of rituximab on clinical and laboratory features of antiphospholipid syndrome: a case report and a review of literature. Lupus 2008, 17:50-55.
14. Rubenstein E., Arkfeld D.G., Metyas S., Shinada S., Ehresmann S., Liebman H.A. Rituximab treatment for resistant antiphospholipid syndrome. J Rheumatol 2006, 33:355-357.
15. Manner H., Jung B., Tonassi L., et al. Successful treatment of catastrophic antiphospholipid antibody syndrome (CAPS) associated with splenic marginal-zone lymphoma with low-molecular weight heparin, rituximab and bendamustine. Am J Med Sci 2008, 335:394-397.
16. van Wissen S., Bastiaansen B.M.J., Stroobants A.K., et al. Catastrophic antiphospholipid syndrome mimicking a malignant pancreatic tumour - a case report. Lupus 2008, 17:586-590.
17. Asherson R.A., Espinosa G., Menahem S., et al. Relapsing catastrophic antiphospholipid syndrome: report of three cases. Semin Arthritis Rheum 2008, 37:377-382.
18. Nageswara Rao A.A., Arteaga G.M., Reed A.M., Gloor J.M., Rodriguez V. Rituximab for successful management of probable pediatric catastrophic antiphospholipid syndrome. Pediatr Blood Cancer 2009, 52:536-538.
19. Jamoussi S.K., Zaghdoudi I., Ben Dhaou B., et al. Catastrophic antiphospholipid syndrome and rituximab: a new report. Tunis Med 2009, 87:699-702.
20. Iglesias-Jiménez E., Camacho-Lovillo M., Falcón-Neyra D., Lirola-Cruz J., Neth O. Infant with probable catastrophic antiphospholipid syndrome successfully managed with rituximab. Pediatrics 2010, 125:e1523-e1528.
21. Haque W., Kadikoy H., Pacha O., Maliakkal J., Hoang V., Abdellatif A. Osteonecrosis secondary to antiphospholipid syndrome: a case report, review of the literature, and treatment strategy. Rheumatol Int 2010, 30:719-723.
22. Morabito F., Gentile M., Gay F., et al. Insights into defibrotide: an updated review. Expert Opin Biol Ther 2009, 9:763-772.
23. Burcoglu-O'ral A., Erkan D., Asherson R. Treatment of catastrophic antiphospholipid syndrome with defibrotide, a proposed vascular endothelial cell modulator. J Rheumato 2002, 29:2006-2011.
24. Asherson R.A., Cervera R., Piette J.C., et al. Catastrophic antiphospholipid syndrome: clues to the pathogenesis from a series of 80 patients. Medicine Baltimore 2001, 80:355-376.
25. Hillmen P., Young N.S., Schubert J., et al. The complement inhibitor eculizumab in paroxysmal nocturnal hemoglobinuria. N Engl J Med 2006, 355:1233-1243.
26. Lucas J.G., Co J.P., Nwaogwugwu U.T., Dosani I., Sureshkumar K.K. Antibody-mediated rejection in kidney transplantation: an update. Expert Opin Pharmacother 2011, 12:579-592.
27. Locke J.E., Magro C.M., Singer A.L., et al. The use of antibody to complement protein C5 for salvage treatment of severe antibody-mediated rejection. Am J Transplant 2009, 9:231-235.
28. Lonze B.E., Singer A.L., Montgomery R.A. Eculizumab and renal transplantation in a patient with CAPS. N Engl J Med 2010, 362:1744-1745.